Financial Results
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sun Pharma reported audited standalone FY2026 revenue of ₹207,546 million, down about 10% from ₹229,774 million in FY2025. However, standalone profit after tax surged 61% to ₹42,281 million from ₹26,234 million, helped by a lower tax outgo due to switching to the concessional tax regime under Section 115BAA. The company recorded exceptional items totaling ₹5,463 million including impairment of SCD-044 drug development assets (₹1,515 million) and costs from new labour codes implementation (₹2,587 million). Auditors issued an unmodified (clean) opinion. The board recommended a final dividend of ₹5 per share, taking total FY2026 dividend to ₹16 per share. A subsidiary merger (five WOSs into Sun Pharma) was approved by NCLT in October 2025, with prior periods restated.
The revenue decline of ~10% is a concern but strong PAT growth driven by tax benefits and cost measures shows operational resilience. The clean audit and dividend continuity are positives for investor confidence.